BeiGene Ltd
(NAS:BGNE)
$
215
8.84 (4.29%)
Market Cap: 23.84 Bil
Enterprise Value: 22.24 Bil
PE Ratio: 0
PB Ratio: 6.64
GF Score: 81/100 Beigene Ltd at Cowen Health Care Conference (Virtual) Transcript
Mar 07, 2022 / 02:50PM GMT
Release Date Price:
$179.73
(+1.91%)
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
And good morning, everybody, or good afternoon or even good evening in this case. Thank you once again for joining us for the 42nd Annual Cowen Healthcare Conference. I'm Yaron Werber, biotech analyst, and it's a great pleasure to moderate the next fireside chat with BeiGene. Today, we have with us John Oyler, who is the CEO; Julia Wang, who is the CFO; Lai Wang, who is the Global Head of R&D; and Kevin Mannix as well, who's VP of IR. So ladies and gentlemen, thanks for joining us. Always good to see you.
John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO
Thank you. Pleasure to be here.
Questions & Answers
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
So we have a half hour and BeiGene is becoming obviously a fairly big company with a huge pipeline and now 2 or actually 3 marketed products that you got approved and then
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot